3billion Launches Family Insight Test, a Family-Based Precision Genomic Testing Service

● Premium WES/WGS Testing for High-Risk Families Facing Infertility, Recurrent Pregnancy Loss, or Inherited Disease Risk

● Expands AI Variant Interpretation Technology to Family-Level Genetic Risk Analysis

● Pilot Testing in Middle East & Africa Confirmed high Demand; leading to service Expansion to Asia and South America

3billion (CEO: Changwon Keum), an AI-powered rare disease diagnostics company, today announced the launch of Family Insight Test, a precision genomic testing service for family-based diagnosis.

Family Insight Test leverages Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) to provide genetic insights for individuals and families who have experienced challenges in pregnancy and childbirth or have a family history of genetic disorders.

While 3billion has focused on identifying genetic causes in symptomatic rare disease patients, Family Insight Test expands the company’s AI variant interpretation technology to analyze genetic risks at the family level before symptoms appear.

The service is designed for high-risk families, including:

• Couples experiencing unexplained infertility or recurrent pregnancy loss
• Cases where direct patient sampling is not feasible, requiring family-based alternative diagnosis
• Individuals seeking to assess personal risk due to family history of genetic disease

As an additional option, Family Insight Test offers Carriership Finding analysis. Unlike standard carrier screening, this analysis targets approximately 2,000 clinically validated core genes to evaluate autosomal recessive and X-linked disorder variants that healthy parents may pass to their children, enabling data-driven family planning.

With this launch, 3billion expands its customer base beyond genetics specialists to include large OB/GYN clinics, In-Vitro Fertilization (IVF) centers, and family planning counseling organizations. Prior to launch, 3billion conducted pilot testing in select regions of the Middle East and Africa where high rates of consanguinity create significant need for genetic risk management, confirming market demand. The company plans to expand the service to high-fertility markets including Asia and South America.

“We have expanded our AI variant interpretation technology, developed through rare disease diagnostics, from the individual to the family level,” said Changwon Keum, CEO of 3billion. “Family Insight Test goes beyond diagnosis to resolve genetic uncertainty faced by patients and high-risk families, helping them plan a safe and clear future. For high-risk couples with a family history of genetic disease, this will serve as a critical decision-making tool for family planning.”

Through Family Insight Test, 3billion is expanding beyond rare disease diagnostics into precision medicine that supports genetic risk analysis and decision-making for individuals and families, strengthening its position as an AI-powered genomic data platform company.

---

About 3billion
3billion is an AI-powered rare disease diagnostics company that leverages proprietary AI variant interpretation technology to deliver rapid and accurate genomic analysis for patients and families worldwide.